Wall Street pulls back after recent rally
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/3/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
BMO Capital Reiterates Outperform on Pfizer (PFE) Following Allergan Merger Termination
April 6, 2016 10:42 AM EDTBMO Capital reiterated an Outperform rating and $39.00 price target on Pfizer (NYSE: PFE) following the company's announcement the merger agreement with Allergan plc was terminated. BMO believes that Pfizer will likely look for more deals to strengthen its innovative business, and the recent weakness... More
Leerink Partners Cuts Price Target on Allergan (AGN) Following New U.S. Treasury Regulations
April 6, 2016 7:13 AM EDTLeerink Partners maintained an Outperform rating on Allergen (NYSE: AGN), and cut the price target to $272.00 (from $340.00), following new U.S. Treasury regulations. The Treasury's temporary regulation regarding new tax inversion rules creates a risk to PFE (MP) - AGN closing.
Analyst Jason Gerberry... More
Northland Capital Markets Downgrades Edwards Lifesciences (EW) to Market Perform (Earlier)
April 5, 2016 10:27 AM EDTNorthland Capital Markets downgraded Edwards Lifesciences (NYSE: EW) from Outperform to Market Perform with a price target of $105.00.
Aanalyst Suraj Kalia commented, "PARTNER-2 intermediate-risk cohort showed that SAPIEN-3 was superior to surgery @ 1-yr in the composite endpoint of all-cause death, stroke and moderate... More
Allergan (AGN), Pfizer (PFE) Comment on U.S. Treasury Action; Won't Comment on Potential Impact
April 5, 2016 6:37 AM EDTPfizer Inc. (NYSE: PFE) and Allergan plc (NYSE: AGN) issued the following statement regarding the recently issued Department of Treasury Notice:
We are conducting a review of the U.S. Department of Treasurys actions announced today. Prior to completing the review, we wont speculate on any potential impact.
... MoreStifel Raises Price Target on Edwards Lifesciences (EW) to $117; Reiterates Buy
April 4, 2016 10:33 AM EDTStifel reiterated a Buy rating on Edwards Lifesciences (NYSE: EW), and raised the price target to $117.00 (from $98.00), following data presentations at American College of Cardiology. Given the outstanding data, Stifel is increasing its 2016-2020 revenue and EPS projections. On EPS, they now project 2016 at $2.67, up $0.06 from prior estimates and 2017 moves to $3.36, up $0.36 or 12% vs prior projection.
Analyst Rick Wise... More
Tesla (TSLA) CEO Musk Says Over 276K Model 3 Pre-Orders Placed
April 4, 2016 7:54 AM EDTTesla (Nasdaq: TSLA) CEO Elon Musk offered additional updates on Model 3 pre-orders and features over the weekend.
In part, Musk said over 276,000 Model 3 pre-orders have been placed.
Musk also noted that the Model 3 will be rear-wheel drive with an option for... More
BTIG Upgrades Edwards Lifesciences (EW) to Buy
April 4, 2016 7:35 AM EDTBTIG upgraded Edwards Lifesciences (NYSE: EW) from Neutral to Buy with a price target of $115. The upgrade follows strong SAPIEN 3... More
